|
Apr 18
|
Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?
|
|
Apr 16
|
Theratechnologies Down 5.6% in U.S. Pre-market After Updating on Sale Process
|
|
Apr 15
|
Theratechnologies Provides Update on Sale Process
|
|
Apr 14
|
Theratechnologies up 22% in U.S. Pre-market Trading, Confirms Buy-out Proposals
|
|
Apr 12
|
Future Pak submits proposals to acquire Theratechnologies
|
|
Apr 12
|
Soleus Capital Issues Letter to The Board of Theratechnologies
|
|
Apr 11
|
Theratechnologies Up 20% In US After Hours As Announces Exclusive Discussions with Another Potential Acquiror
|
|
Apr 11
|
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
|
|
Apr 11
|
Theratechnologies Shares Jump 42% After Future Pak's $255 Million Takeover Bid
|
|
Apr 11
|
Theratechnologies Receives Buyout Offer from Future Pak at $3.51 to $4.50 per Share
|
|
Apr 10
|
Theratechnologies Inc (THTX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
|
|
Apr 9
|
Theratechnologies Swings to Q1 Profit as Sales Advance
|
|
Apr 9
|
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
|
|
Mar 12
|
Theratechnologies Presents Ibalizumab Data in Virologic Suppression
|
|
Mar 12
|
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
|
|
Mar 12
|
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
|
|
Oct 17
|
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
|
|
Oct 17
|
Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab
|
|
Oct 17
|
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
|
|
Oct 11
|
Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|